Cell No. : Cell Name RCB5667 : Y-MESO-12  update : 2024/11/11
Comment
Comment from the depositor			Human malignant pleural mesothelioma cell line. This cell line was established from the tumor tissue (epithelioid type MPM) of a patient. This cell line has a homozogous deletion of the NF2 gene.
Terms and conditions			In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature (Cancer Sci 2007 98(3):438-46) designated by the DEPOSITOR is requested.
Remarks
Order Form			Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	Depositor	SEKIDO, Yoshitaka
		Originator	SEKIDO, Yoshitaka
		Year of deposit	2022
		Cloning (depositor)	No
		Animal	_human < Mammals
		Genus	Homo
		Species	sapiens
		Race	Japanese
		Gender	Female
		Age at sampling	71 years
		Tissue	tumor tissue
		Primary focus	malignant pleural mesothelioma
		Disease name	malignant pleural mesothelioma
		Tumor	epithelioid type MPM
		Classification	cancer
		Recombinant	non-recombinant
		Lifespan	infinite
		Morphology	epithelial-like
		Cellosaurus(Expasy)	CVCL_5178
			deposit info	lot info
		Medium	Medium List
		Culture type	Adherent cells	Adherent cells
		Culture medium	RPMI1640 + 10% FBS	RPMI1640 + 10% FBS
		Antibiotics	1% antimicrobial	Free
		Passage method		0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
	Culture information	Passage ratio	1 : 5-8 split	1 : 5-8 split
		SC frequency	Subculture : 1-2 times/week	Subculture : 1-2 times/week
		Temperature	37 ℃	37 ℃
		CO2 concentration	5 %	5 %
		Freeze medium		CELLBANKER 1
		Freezing method		Slow freezing
		Mycoplasma/Acholeplasma		(-)
		Mycoplasma	(-)
		Animal PCR		OK
		Virus (HIV)	(-)
		Virus (HBV)	(-)
		Virus (HCV)	(-)
		STR(human)		OK
		deposit info	D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO 12 8, 12 11 11,13 16,18 6,9 X 8 10
		lot info	D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO 12 8,12 11 11,13 16,18 6,9 X 8 10
Reference information		Reference	22
		User's Publication	0

Top

Reference

17591  Hagiyama M, Mimae T, Wada A, Takeuchi F, Yoneshige A, Inoue T, Kotoku N, Hamada H, Sekido Y, Okada M, Ito A.  Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma  Front Cell Dev Biol  2022  10:945007.  PubMed ID: 35903548   DOI: 10.3389/fcell.2022.945007

20921  Koya Suzuki, Masaki Tange, Ryota Yamagishi, Hiroyuki Hanada, Satomi Mukai, Tatsuhiro Sato, Takeshi Tanaka, Tomohiro Akashi, Kenji Kadomatsu, Tohru Maeda, Takashi Miida, Ichiro Takeuchi, Hiroshi Murakami, Yoshitaka Sekido & Yuko Murakami-Tonami  SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated malignant mesothelioma  Cell Death Discovery  2022  8, Article number: 446  PubMed ID: 36335095   DOI: 10.1038/s41420-022-01232-w

16466  Sato T, Mukai S, Ikeda H, Mishiro-Sato E, Akao K, Kobayashi T, Hino O, Shimono W, Shibagaki Y, Hattori S, Sekido Y.  Silencing of SmgGDS, a Novel mTORC1 Inducer That Binds to RHEBs, Inhibits Malignant Mesothelioma Cell Proliferation  Mol Cancer Res  2021  19(5):921-931  PubMed ID: 33574130   DOI: 10.1158/1541-7786.MCR-20-0637

16452  Okazaki Y, Misawa N, Akatsuka S, Kohyama N, Sekido Y, Takahashi T, Toyokuni S.  Frequent homozygous deletion of Cdkn2a/2b in tremolite-induced malignant mesothelioma in rats  Cancer Sci  2020  111(4):1180-1192.  PubMed ID: 32080953   DOI: 10.1111/cas.14358

16027  Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, Aoki M, Hasegawa Y, Sekido Y.  TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation  Oncogene  2018  38(11):1966-1978  PubMed ID: 30401981   DOI: 10.1038/s41388-018-0417-7

16453  Ohara Y, Chew SH, Misawa N, Wang S, Somiya D, Nakamura K, Kajiyama H, Kikkawa F, Tsuyuki Y, Jiang L, Yamashita K, Sekido Y, Lipson KE, Toyokuni S.  Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model  Oncotarget  2018  9(26):18494-18509  PubMed ID: 29719620   DOI: 10.18632/oncotarget.24892

10639  Shigeeda W, Shibazaki M, Yasuhira S, Masuda T, Tanita T, Kaneko Y, Sato T, Sekido Y, Maesawa C.  Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma.  Oncotarget  2017  8:93729-93740  PubMed ID: 29212185   DOI: 10.18632/oncotarget.20750

16454  Chew SH, Okazaki Y, Akatsuka S, Wang S, Jiang L, Ohara Y, Ito F, Saya H, Sekido Y, Toyokuni S.  Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma  Free Radic Biol Med  2017  106:91-99  PubMed ID: 28185919   DOI: 10.1016/j.freeradbiomed.2017.02.011

16467  Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y.  Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis  Cancer Lett  2017  385:215-224.  PubMed ID: 27773750   DOI: 10.1016/j.canlet.2016.10.020

16477  Kato T, Sato T, Yokoi K, Sekido Y.  E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells  Oncogene  2017  36(39):5522-5531  PubMed ID: 28553954   DOI: 10.1038/onc.2017.147

16460  Li Q, Wang W, Machino Y, Yamada T, Kita K, Oshima M, Sekido Y, Tsuchiya M, Suzuki Y, Nan-Ya K, Iida S, Nakamura K, Iwakiri S, Itoi K, Yano S.  Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma  Cancer Sci  2015  106(1):102-7  PubMed ID: 25421609   DOI: 10.1111/cas.12575

16468  Hakiri S, Osada H, Ishiguro F, Murakami H, Murakami-Tonami Y, Yokoi K, Sekido Y.  Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells  Cancer Sci  2015  106(8):990-9.  PubMed ID: 26011428   DOI: 10.1111/cas.12698

16469  Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T, Sekido Y.  LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade  Oncogene  2015  34(1):73-83  PubMed ID: 24336325   DOI: 10.1038/onc.2013.528

16461  Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y.  A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody  J Immunol  2013  190(12):6239-49  PubMed ID: 23690472   DOI: 10.4049/jimmunol.1300448

16456  Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y.  Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells  Ann Surg Oncol  2012  19 Suppl 3(Suppl 3):S634-45  PubMed ID: 22086445   DOI: 10.1245/s10434-011-2142-0

16470  Elshazley M, Sato M, Hase T, Yamashita R, Yoshida K, Toyokuni S, Ishiguro F, Osada H, Sekido Y, Yokoi K, Usami N, Shames DS, Kondo M, Gazdar AF, Minna JD, Hasegawa Y.  The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma  Int J Cancer  2012  131(12):2820-31  PubMed ID: 22510946   DOI: 10.1002/ijc.27598

16471  Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y, Akatsuka S, Toyokuni S, Yokoi K, Osada H, Sekido Y.  YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes  Oncogene  2012  31(49):5117-22  PubMed ID: 22286761   DOI: 10.1038/onc.2012.5

16472  Ishiguro F, Murakami H, Mizuno T, Fujii M, Kondo Y, Usami N, Yokoi K, Osada H, Sekido Y.  Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma  J Thorac Oncol  2012  7(5):890-9  PubMed ID: 22722789   DOI: 10.1097/JTO.0b013e31824af2db

16474  Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, Toyokuni S, Osada H, Sekido Y.  LATS2 is a tumor suppressor gene of malignant mesothelioma  Cancer Res  2011  71(3):873-83  PubMed ID: 21245096   DOI: 10.1158/0008-5472.CAN-10-2164

16457  Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y.  Activation of the PI3K-AKT pathway in human malignant mesothelioma cells  Mol Med Rep  2009  2(2):181-8  PubMed ID: 21475810   DOI: 10.3892/mmr_00000081

16475  Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y.  Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells  Carcinogenesis  2009  30(7):1097-105  PubMed ID: 19380521   DOI: 10.1093/carcin/bgp097

16458  Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, Yatabe Y, Seto M, Sekido Y.  Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32  Cancer Sci  2007  98(3):438-46  PubMed ID: 17270034   DOI: 10.1111/j.1349-7006.2006.00386.x

Top

User's Publication